St. Jude Medical, which was acquired by Abbott Laboratories in 2017, agreed to pay $27 million to settle allegations the company knowingly sold defective heart devices, the U.S. Justice Department said on July 8.
Abbott’s Xience family of stents received U.S. Food and Drug Administration approval for one-month (as short as 28 days) dual anti-platelet therapy labeling for high bleeding risk patients in the United States.
GALIEN DIGITAL HEALTH WEBINAR SERIES The Incubators of Innovation: Academic Medical Centers As Digital Health Champions THURSDAY, JUNE 24, 2021 1:00 PM – 2:00 PM ET Register Academic medical center incubators are launching pads for digital health, medical device and health information startups as they develop and prepare their ideas and innovations for market entry. […]
Clinical Ink’s white paper discusses BYOD advantages and misconceptions, regulatory, copyright, and equivalency considerations, and a Phase III case study.
The U.S. Food and Drug Administration granted accelerated approval of Janssen’s Rybrevant (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
AbbVie Inc.’s Allergan Aesthetics announced the acquisition of Soliton Inc. in a definitive agreement that is valued at $550 million. Allergan Aesthetics will pay $22.60 per share for each outstanding Soliton share.
Dentsu International announced on April 20 the launch of dentsu health, a global solution. Drawing upon the expertise of dentsu’s global network of 2,000 health marketing experts across 85 markets in EMEA, APAC and the Americas, dentsu health is poised to become one of the top global healthcare agencies.
Thermo Fisher Scientific Inc. is acquiring contract researcher PPD Inc. for $17.4 billion as the medical device maker adds more muscle to the company’s pharmaceutical services business.
Mayo Clinic launched two new tech venture companies designed to harness artificial intelligence (AI) and medical algorithms and create “software as medical devices” that clinicians can use to improve treatment across different diseases.
Studies have concluded that chatbots have the potential in treating mental health issues and could be used as an effective tool for delivering cognitive behavioral therapy.